How This Class Works

Despite diverse structures, several nootropic peptides converge on upregulation of brain-derived neurotrophic factor (BDNF), a neurotrophin critical for the growth, differentiation, and survival of neurons, as well as synaptic plasticity underlying learning and memory. BDNF interacts primarily with the TrkB receptor. Both Semax and Selank have been documented to increase BDNF expression in animal and in vitro models, though through different upstream mechanisms. BDNF upregulation is associated with cognitive enhancement, antidepressant effects, and neuroprotection.

Semax (an ACTH 4-10 synthetic analogue) lacks ACTH's adrenal-stimulating properties but retains neuroprotective signalling, modulating serotonin and dopamine synthesis and activating HIF-1α-mediated neuroprotective pathways. Selank (a tuftsin-derived heptapeptide) has a more anxiolytic profile, modulating serotonin transporter activity and interacting with enkephalin degradation pathways to reduce anxiety-like behaviours in animal models without sedation. Dihexa works through a distinct mechanism — potentiating HGF (hepatocyte growth factor) signalling via the c-Met receptor, which promotes synaptogenesis and has been investigated in Alzheimer's disease models.

Most nootropic peptides in this class were developed in Russia by institutes including the Institute of Molecular Genetics and the Valdman Institute. Semax and Selank are approved as nasal spray pharmaceuticals in Russia and some former Soviet states for indications including cerebrovascular disorders, stress, and cognitive decline. This regulatory approval history provides a level of human safety data not typical for peptides of non-pharmaceutical origin, though controlled trial data outside Russia is limited.

Research Context

Soviet and Russian peptide neuropsychopharmacology emerged from the 1970s–90s. Semax originated from research into ACTH 4–10 and its CNS effects independent of adrenal stimulation. Selank was designed as a tuftsin analogue with anxiolytic properties without benzodiazepine-type sedation or dependence liability. Both have been used clinically in Russia for decades.

Research has investigated nootropic peptides for their potential role in cognitive enhancement in healthy subjects, cognitive decline in aging, anxiety and stress-related conditions, post-stroke recovery, and neuroprotection against oxidative and ischemic insults. The intranasal route used for Semax and Selank enables direct CNS delivery via the olfactory pathway, avoiding the first-pass degradation that makes most peptides orally inactive.

Individual Compound Notes